In this video interview, Guillermo Garcia-Manero, MD, chief of the section of myelodysplastic syndromes at the University of Texas MD Anderson Cancer Center, discusses data from a preplanned analysis of the COMMANDS trial presented at ASCO® 2025 in Chicago.
In this preplanned analysis, patients with transfusion-dependent, lower-risk myelodysplastic syndromes (MDS) receiving luspatercept as first-line therapy showed a significant survival advantage over those treated with erythropoiesis-stimulating agents (ESAs).
Dr. Garcia-Manero called the data “transformative.” “Traditionally, when we design clinical trials for lower-risk MDS, we don’t think about survival… and now, for the first time in a phase 3 study, we’re starting to see that patients treated with luspatercept have significantly longer survival compared to those treated with ESAs.”
Reference
Garcia-Manero G, Della Porta M, Zeidan A. Overall survival (OS) and duration of response for transfusion independence (TI) in erythropoiesis stimulating agent (ESA)–naive patients (pts) with very low-, low-, or intermediate-risk myelodysplastic syndromes (MDS) treated with luspatercept (LUSPA) vs epoetin alfa (EA) in the COMMANDS trial. Abstract #6512. Presented at the 2025 ASCO® Annual Meeting; May 30-June 3, 2025; Chicago.
